Wells Fargo Maintains Equal-Weight on Cellectis, Lowers Price Target to $3
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Yanan Zhu maintains Cellectis (NASDAQ:CLLS) with a Equal-Weight and lowers the price target from $4 to $3.
Wells Fargo analyst Yanan Zhu maintains Cellectis (NASDAQ:CLLS) with a Equal-Weight and lowers the price target from $4 to $3.